Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Anemia affects almost 1 in 4 people worldwide. But while billions of people live with the disease, its signs and symptoms aren’t just part of everyday life. “Anemia is one of the most common global ...

You probably know that anemia makes you feel tired and weak, but what you might not realize is that your iron-deficient blood is forcing your heart to work overtime in ways that could permanently ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

An oral pyruvate kinase (PK) activator, mitapivat becomes the only approved option for treating anemia in both ...

DOCTOR, ANEMIA IS A CONDITION THAT AFFECTS 30% OF PEOPLE ACROSS THE WORLD. BUT IT’S MORE COMMON IN WOMEN THAN MEN. ANEMIA IS WHEN YOU HAVE LOW HEMOGLOBIN LEVELS. HEMOGLOBIN GIVES YOUR BLOOD ITS RED ...

Even though anemia is not as common in the United States (affecting roughly 10 percent of people) as it is worldwide (affecting nearly 30 percent of people), it often affects more women than men and ...

The Prevalence of Anemia Among Women Anemia, particularly iron deficiency, is a widespread issue affecting many women, ...

Hemolytic disease of the newborn is a type of anemia that begins during pregnancy. It can cause serious illness in a newborn, but it may be diagnosed during prenatal screening and treated to avoid ...